5 Key Takeaways

• 1

  The FDA has approved Afrezza for children aged 6 and older with type 1 or type 2 diabetes.

• 2

  Afrezza is an inhaled mealtime insulin that is administered using a portable inhaler.

• 3

  The approval was supported by data from the INHALE-1 trial and over 20 years of inhaled insulin studies.

• 4

  Afrezza offers a needle-free option for mealtime insulin, addressing challenges faced by pediatric patients.

• 5

  Afrezza is not suitable for patients with chronic lung diseases and requires lung function assessments.